Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565
   PubMed Web of Science ®Google Scholar
• Tone Y, Tanahashi N, Tanaka K, et al. Nob1p, a new essential protein, associates with the 26S proteasome of growing Saccharomyces cerevisiae cells. Gene. 2000;243(1–2):37–45. doi:10.1016/s0378-1119(99)00566-1
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ni J, Zhou G, et al. Cloning, expression and characterization of the human NOB1 gene. Mol Biol Rep. 2005;32(3):185–189. doi:10.1007/s11033-005-3141-7
   PubMed Web of Science ®Google Scholar
• Tone Y, Toh-e A. Nob1p is required for biogenesis of the 26S proteasome and degraded upon its maturation in Saccharomyces cerevisiae. Genes Dev. 2002;16(24):3142–3157. doi:10.1101/gad.1025602
   PubMed Web of Science ®Google Scholar
• Zhou G-J, Zhang Y, Wang J, et al. Cloning and characterization of a novel human RNA binding protein gene PNO1. DNA Seq. 2004;15(3):219–224. doi:10.1080/10425170410001702159
   PubMed Web of Science ®Google Scholar
• Granneman S, Petfalski E, Swiatkowska A, et al. Cracking pre-40S ribosomal subunit structure by systematic analyses of RNA-protein cross-linking. EMBO J. 2010;29(12):2026–2036. doi:10.1038/emboj.2010.86
   PubMed Web of Science ®Google Scholar
• Ke W, Lu Z, Zhao X. NOB1: a potential biomarker or target in cancer. Curr Drug Targets. 2019;20(10):1081–1089. doi:10.2174/1389450120666190308145346
   PubMed Web of Science ®Google Scholar
• Luo L, Wang Y, Yin Y, et al. Effects of NOB1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin. Oncol Lett. 2018;15(3):3548–3551. doi:10.3892/ol.2018.7730
   PubMed Web of Science ®Google Scholar
• Qi H, Wang Y. NOB1 gene as a potential biomarker in clinical outcomes and prognosis of patients with gastric cancer. Clin Lab. 2018;64(9):1469–1475. doi:10.7754/Clin.Lab.2018.180330
   PubMed Web of Science ®Google Scholar
• Jin Y, Zhou X, Yao X, et al. MicroRNA-612 inhibits cervical cancer progression by targeting NOB1. J Cell Mol Med. 2020;24(5):3149–3156. doi:10.1111/jcmm.14985
   PubMed Web of Science ®Google Scholar
• Wang J, Cao L, Wu J, et al. Long non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma. Int J Oncol. 2018;52(1):77–88. doi:10.3892/ijo.2017.4187
   PubMed Web of Science ®Google Scholar
• Deng Y, Li Y, Fang Q, et al. microRNA-744 is downregulated in glioblastoma and inhibits the aggressive behaviors by directly targeting NOB1. Am J Cancer Res. 2018;8(11):2238–2253.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34. doi:10.1016/j.jclinepi.2009.06.006
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):1–16. doi:10.1186/1745-6215-8-16
   PubMedGoogle Scholar
• Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014;14(1):1–5. doi:10.1186/1471-2288-14-45
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi:10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. doi:10.2307/2533446
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Che J-P, Li W, Yan Y, et al. Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma. Int J Clin Exp Pathol. 2013;6(11):2300.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang J, Cui X, et al. Positive nin one binding protein expression predicts poor outcome in prostate cancer. Mol Med Rep. 2015;11(4):2671–2676. doi:10.3892/mmr.2014.3066
   PubMed Web of Science ®Google Scholar
• Jia J-W, Liu A-Q, Wang Y, et al. Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells. Tumour Biol. 2015;36(3):1803–1810. doi:10.1007/s13277-014-2783-2
   PubMedGoogle Scholar
• Li X-Y, Luo Q-F, Li J, et al. Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma. Int J Clin Exp Pathol. 2013;6(10):2137.
   PubMed Web of Science ®Google Scholar
• Lin S, Meng W, Zhang W, et al. Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma. J Int Med Res. 2013;41(3):568–572. doi:10.1177/0300060513479862
   PubMed Web of Science ®Google Scholar
• Liu G, Shen D, Jiao L, et al. Nin one binding protein expression as a prognostic marker in prostate carcinoma. Clin Transl Oncol. 2014;16:843–847. doi:10.1007/s12094-014-1158-x
   PubMed Web of Science ®Google Scholar
• Liu K, Chen H-L, Gu M-M, et al. Relationship between NOB1 expression and prognosis of resected non-small cell lung cancer. Int J Biol Markers. 2015;30(1):43–48. doi:10.5301/jbm.5000120
   Web of Science ®Google Scholar
• Liu K, Chen H-L, Gu M-M, et al. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer. Int J Clin Exp Pathol. 2015;8(12):16081.
   PubMed Web of Science ®Google Scholar
• Qi H, Wang Y. NOB1 gene as a potential biomarker in clinical outcomes and prognosis of patients with gastric cancer. Clin Lab. 2018;64(9):1469–1475. doi:10.7754/Clin.Lab.2018.180330
   PubMed Web of Science ®Google Scholar
• Wang H, Li P, Zhao B. Knockdown of NOB1 expression by RNAi inhibits cellular proliferation and migration in human gliomas. Gene. 2013;528(2):146–153. doi:10.1016/j.gene.2013.07.032
   PubMed Web of Science ®Google Scholar
• Wu L, Hui H, Wang L-J, et al. MicroRNA-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein. Oncol Rep. 2015;33(5):2309–2318. doi:10.3892/or.2015.3840
   PubMed Web of Science ®Google Scholar
• Yin J, Wang J, Jiang Y, et al. Downregulation of NOB1 inhibits proliferation and promotes apoptosis in human oral squamous cell carcinoma. Oncol Rep. 2015;34(6):3077–3087. doi:10.3892/or.2015.4271
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang F, Wang L, et al. MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1. World J Surg Oncol. 2020;18:1–11. doi:10.1186/s12957-020-01859-y
   Web of Science ®Google Scholar
• Zhou W, Liu X, Yang Y, et al. Expression mechanism and clinical significance of Nob1 in gastric cancer tissue and adjacent normal tissue. J Biol Regul Homeost Agents. 2015;29:423–430.
   PubMed Web of Science ®Google Scholar
• Kailemia MJ, Park D, Lebrilla CB. Glycans and glycoproteins as specific biomarkers for cancer. Anal Bioanal Chem. 2017;409(2):395–410. doi:10.1007/s00216-016-9880-6
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Yip KW, Spence T, et al. MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet. 2017;62(1):67–74. doi:10.1038/jhg.2016.87
   PubMed Web of Science ®Google Scholar
• Skotland T, Ekroos K, Kauhanen D, et al. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur J Cancer. 2017;70:122–132. doi:10.1016/j.ejca.2016.10.011
   PubMed Web of Science ®Google Scholar
• Kong R, Liu W, Guo Y, et al. Inhibition of NOB1 by microRNA-330-5p overexpression represses cell growth of non-small cell lung cancer. Oncol Rep. 2017;38(4):2572–2580. doi:10.3892/or.2017.5927
   PubMed Web of Science ®Google Scholar
• Ding F, Xiao H, Wang M, et al. The role of the ubiquitin-proteasome pathway in cancer development and treatment. Front Biosci (Landmark Ed). 2014;19:886–895. doi:10.2741/4254
   PubMed Web of Science ®Google Scholar
• Jain KC, Arora S, Khanna A, et al. The ubiquitin-proteasome pathway an emerging anticancer strategy for therapeutics: a patent analysis. Recent Pat Anticancer Drug Discov. 2015;10(2):201–213. doi:10.2174/1574892810666150416111213
   PubMed Web of Science ®Google Scholar
• Johnson DE. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 2015;22(1):T1–T17. doi:10.1530/ERC-14-0005
   PubMed Web of Science ®Google Scholar
• Patwardhan GA, Liu Y-Y. Sphingolipids and expression regulation of genes in cancer. Prog Lipid Res. 2011;50(1):104–114. doi:10.1016/j.plipres.2010.10.003
   PubMed Web of Science ®Google Scholar